Easily Send & Share Press Releases
If you make changes to this saved search, you'll find the original and new searches in your account.
Your search filters:
Narrow by:
Show Top 5
Show All
Show More
Showing 1-10 of about 64 articles.
Repros Therapeutics Inc.
FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 8 hours ago
Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results
THE WOODLANDS, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 12 days ago
Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule
THE WOODLANDS, Texas, May 2, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 20 days ago
Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University
THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 23 days ago
Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents
THE WOODLANDS, Texas, April 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 42 days ago
Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)
THE WOODLANDS, Texas, March 27, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 56 days ago
American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting
THE WOODLANDS, Texas, March 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 58 days ago
Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results
THE WOODLANDS, Texas, March 18, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 65 days ago
FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design
THE WOODLANDS, Texas, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.
about 83 days ago